7
Participants
Start Date
September 22, 2020
Primary Completion Date
February 8, 2023
Study Completion Date
November 30, 2023
FT596
FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
Rituximab
Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
University of Minnesota, Minneapolis
Washington University School of Medicine - Siteman Cancer Center, St Louis
National Cancer Institute (NCI)
NIH
Masonic Cancer Center, University of Minnesota
OTHER